Icagen boosted by upbeat mid-stage results for asthma

Shares of Research Triangle Park, NC-based Icagen were buoyed this morning on the news that its experimental allergic asthma therapy proved promising in a mid-stage trial.

Researchers for the developer say that senicapoc improved every measure of asthmatic response to inhaled allergens in the small Phase IIa study, with the placebo group showing no improvement. The company recruited 34 patients for the study. Icagen shares shot up 20 percent on the announcement.

"We are pleased with the results of this study, and believe that they justify further evaluation of senicapoc as a novel approach to the treatment of asthma," said Seth Hetherington, senior vice president of clinical and regulatory affairs.

- read the Icagen release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.